Results 201 to 210 of about 229,436 (314)

Forecasting heart failure: Seasonal alignment of heart failure outcomes in New York

ESC Heart Failure, Volume 12, Issue 2, Page 819-831, April 2025.
Abstract Background Seasonal variations have been observed in heart failure (HF) hospitalization. Numerous explanatory mechanisms have been proposed, but no prior studies have examined potential contributors directly. Our objective was to identify specific factors that could contribute to seasonal variability using a large longitudinal dataset of HF ...
Prerna Gupta, Ellen Brinza, Prateeti Khazanie, Pamela N. Peterson, P Michael Ho, David P. Kao   +5 more
wiley   +1 more source

The immune-cardiovascular metabolic circuitry in myocardial ischemia-reperfusion injury: from metabolic signal release to spatiotemporal reprogramming. [PDF]

Front Immunol
Tan C, Zhou J, Li J, Zhang X, Yuan W.
europepmc   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Purine Nucleotide Precursors in Preventing Myocardial Ischemia-Reperfusion Injury. [PDF]

Int J Mol Sci
Musial PT, Badtke PA, Zabielska-Kaczorowska MA.   +2 more
europepmc   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

Ozone Administration Reduces Myocardial Ischemia Reperfusion Injury in Streptozotocin Induced Diabetes Mellitus Rat Model

Mehmet Burak Gülcan,1 Hüseyin Demirtaş,2 Abdullah Özer,2 Zeynep Yığman,3,4 Ali Dogan Dursun,5 Mustafa Arslan,6– 8 Gürsel Levent Oktar2 1Erzurum City Hospital, Department of Cardiovascular Surgery, Erzurum, Turkey; 2Gazi University ...
Gülcan MB, Özer A, Dursun AD, Demirtaş H, Oktar GL, Arslan M, Yığman Z   +6 more
core  

Molecular and Cellular Mechanisms of Myocardial Ischemia and Reperfusion Injury: A Narrative Review. [PDF]

Cells
Juricic S, Klac J, Stojkovic S, Beleslin B, Tesic M, Jovanovic I, Banovic M, Petrovic O, Aleksandric S, Vasic N, Simeunovic F, Lazovic D, Stoiljkovic M, Nikolov S, Simeunovic D.   +14 more
europepmc   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Isovitexin Alleviates Myocardial Ischemia by Targeting SLC25A4 and Modulating the AMPK/PGC-1<i>α</i> Signaling Pathway. [PDF]

Int J Mol Sci
He Z, Shan Z, Zhou Y.
europepmc   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source